We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$121M
Cap. Flow %
-3.08%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Financials 0.15%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NOW icon
76
ServiceNow
NOW
$132B
$1.97M 0.05%
+12,500
New +$1.83M
OVID icon
77
Ovid Therapeutics
OVID
$523M
$1.92M 0.05%
2,500,000
– –
GRTS
78
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.87M 0.05%
3,030,952
+2,000,000
+194% +$1.69M
PEPG icon
79
PepGen
PEPG
$206M
$1.81M 0.05%
113,317
-86,683
-43% -$1.24M
PANW icon
80
Palo Alto Networks
PANW
$323B
$1.53M 0.04%
9,000
+3,000
+50% +$449K
PYPL icon
81
CALL
PayPal
PYPL
$51.8B
$1.51M 0.04%
26,000
-32,000
-55% -$2.04M
KYTX icon
82
Kyverna Therapeutics
KYTX
$500M
$1.5M 0.04%
200,000
– –
QCOM icon
83
Qualcomm
QCOM
$173B
$1.49M 0.04%
+7,500
New +$1.42M
JBIO
84
Jade Biosciences
JBIO
$1.51B
$1.34M 0.03%
+23,131
New +$15.3M
GOOGL icon
85
Alphabet (Google) Class A
GOOGL
$4.24T
$1.28M 0.03%
7,000
– –
MGX icon
86
Metagenomi Therapeutics
MGX
$46.5M
$1.22M 0.03%
300,000
– –
TRML
87
DELISTED
Tourmaline Bio
TRML
$1.18M 0.03%
91,426
-223,070
-71% -$3.59M
RBRK icon
88
Rubrik
RBRK
$21.6B
$1.07M 0.03%
+35,000
New +$1.15M
KRON
89
DELISTED
Kronos Bio
KRON
$1.05M 0.03%
842,954
– –
MDB icon
90
MongoDB
MDB
$38B
$1.01M 0.03%
4,021
+2,021
+101% +$638K
EDU icon
91
New Oriental
EDU
$8.33B
$972K 0.02%
12,500
-2,500
-17% -$204K
BZ icon
92
Kanzhun
BZ
$6.89B
$941K 0.02%
+50,000
New +$1.01M
FROG icon
93
JFrog
FROG
$11.5B
$939K 0.02%
+25,000
New +$916K
PYPL icon
94
PayPal
PYPL
$51.8B
$870K 0.02%
15,000
+5,000
+50% +$318K
INTC icon
95
Intel
INTC
$527B
$774K 0.02%
+25,000
New +$819K
IRWD icon
96
Ironwood Pharmaceuticals
IRWD
$674M
$721K 0.02%
110,532
– –
PEGA icon
97
Pegasystems
PEGA
$5.51B
$696K 0.02%
23,000
– –
SNOW icon
98
Snowflake
SNOW
$117B
$682K 0.02%
5,051
-1,449
-22% -$214K
ACHL
99
DELISTED
Achilles Therapeutics
ACHL
$616K 0.02%
755,375
– –
CFLT
100
DELISTED
Confluent
CFLT
$561K 0.01%
19,000
– –
2 3
4
5 6

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group withdrew a net $121M in Q2 2024, closing 20 positions and reducing 29 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $29.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Artal Group opened a new position in Cullinan Oncology worth $18.5M.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.